Clinical Pharmacology & Biopharmaceutics
Open Access

Translational Pharmacokinetics: Bridging Bench to Bedside

Received Date: Jun 04, 2024 / Published Date: Jun 28, 2024

Copyright: © 0  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

To read the full article Peer-reviewed Article PDF

Abstract:

Translational pharmacokinetics (PK) is crucial in bridging the gap between preclinical drug research and clinical application, providing essential insights into a drug's absorption, distribution, metabolism, and excretion (ADME). This article explores the importance of PK in drug development, highlighting the transition from laboratory studies to clinical practice. Key stages in this transition include preclinical PK studies, scaling and modeling, first-in-human studies, and extensive clinical trials. The case study of Infliximab, a monoclonal antibody used to treat chronic inflammatory diseases, illustrates the application of translational PK. Despite challenges such as inter-species differences and biological complexity, advancements in modeling techniques and personalized medicine hold promise for improving drug development and patient care.

Keywords